Date Release
November 25 Largest Prospective Study Evaluating the Effect of Vigabatrin on Vision
October 21 Connect 4 Mental Health™ Announces 2015 Community Innovation Award Recipients
August 10 FDA Accepts a Supplemental New Drug Application for Review of Brintellix® (vortioxetine) Clinical Trial Data That Assessed Cognitive Function in Patients with Major Depressive Disorder
August 7 Lundbeck Joins Innovative Alzheimer’s Disease Research Initiative
July 30 FDA Approves Deltoid Injection Site for Abilify Maintena® (aripiprazole) for extended-release injectable suspension in the Treatment of Schizophrenia
July 10 U.S. FDA Approves Otsuka and Lundbeck’s REXULTI® (brexpiprazole) as Adjunctive Treatment for Adults with Major Depressive Disorder and as a Treatment for Adults with Schizophrenia
June 22 Survey Results Imply Adults with Schizophrenia, Caregivers Frustrated by Tradeoffs in Managing Symptoms and Medication Side Effects
June 15 Analysis of Responder Data from Clinical Trials Evaluating NORTHERA® (droxidopa) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
May 28 Eight Data Presentations on Lundbeck Therapy for Rare Neurological Disorder at MDS Annual Meeting 
May 18 New Petition To Help Build Awareness of Major Depressive Disorder (MDD), One of the Most Common Mental Disorders in the U.S.
May 12 Otsuka and Lundbeck to Present Data on Investigational Compound brexpiprazole in Schizophrenia and Major Depressive Disorder at American Psychiatric Association Annual Meeting
May 11 Connect 4 Mental Health™ Announces 2015 Community Innovation Awards Call for Entries
April 17 Results of Phase III Study of Brexpiprazole in Adult Patients with Schizophrenia Published in American Journal of Psychiatry
April 14 Lundbeck and ‘Keep Memory Alive’ Invest to Support Multiple System Atrophy Research and Global Taskforce



Contact Us

Sally Benjamin Young
Vice President, Public Affairs
Email: SYOU@lundbeck.com
Phone: (847) 282-5770

Matt Flesch
Director, Public Relations
Email: MFLE@lundbeck.com
Phone: (847) 282-1154

Follow us on Twitter!

Get our latest company news.
Click here

You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit. Click OK to continue or Cancel to return to Lundbeck.